Nipple Inflammation: An Unusual Adverse Effect from Vemurafenib, A V600E BRAF Inhibitor during Off-Lable Treatment for Anaplastic Thyroid Carcinoma

Anaplastic thyroid cancer is regarded as one of the most aggressive of all solid malignant tumors. Until recently the prognosis for patients with these cancers was almost universally bleak with an expected median life expectancy of about 5-months. Although traditional chemotherapy or radiation therapy offers little chance of cure, targeted therapy against mutant tyrosine kinase inhibitors such as BRAF-V600, may give some hope in treatment of these aggressive cancers. The following case report adds information to the well-known cutaneous adverse effects associated with targeted therapy with vemurafenib, an inhibitor of BRAF-V600.

 

View Full Article: HERE

Go through the Journal:  http://www.enlivenarchive.org/clinical-dermatology

Contact Us: dermatology@enlivenarchive.org

 

Leave a Reply

Your email address will not be published. Required fields are marked *